



# Glaukos Announces Participation in Bank of America Merrill Lynch 2019 Health Care Conference

2019-04-30

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019, at 3:40 p.m. PDT in Las Vegas, Nevada.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at <http://investors.glaukos.com> and will be archived for 90 days.

## About Glaukos

Glaukos ([www.glaukos.com](http://www.glaukos.com)) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world's leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the *iStent*<sup>®</sup>, its first MIGS device, in the United States in July 2012 and launched its next-generation *iStent inject*<sup>®</sup> device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the *iStent inject*, measuring 0.23 mm wide and 0.36 mm long, is the smallest medical device ever approved by the FDA.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20190430005091/en/): <https://www.businesswire.com/news/home/20190430005091/en/>

Chris Lewis  
Director, Investor Relations, Corporate Strategy & Development  
(949) 481-0510  
[clewis@glaukos.com](mailto:clewis@glaukos.com)

Source: Glaukos Corporation